Radotinib Dose Reduction for Chronic Phase CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if lowering the dose of radotinib is safe and effective for adults newly diagnosed with a certain type of leukemia (chronic phase CML). It may help control the disease while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have been diagnosed with chronic phase CML within the last 8 weeks.
- You have a specific gene change (Philadelphia chromosome or BCR-ABL) in your leukemia cells.
- You are in good enough health to carry out daily activities (ECOG score 0-2).
- You have adequate liver, kidney, and pancreas function based on blood tests.
- You are not taking certain other cancer drugs, have not used radotinib for 8 days or more, and have no major heart issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
This Phase 2 study tests whether radotinib is safe and tolerable, and whether it can help people with early Parkinson’s disease. It also checks how the body absorbs and processes the drug.
This trial studies a new drug (KRT-232) combined with a standard CML “TKI” medicine to treat chronic myeloid leukemia (CML) that is resistant or not tolerated after at least one prior TKI. It may help people whose leukemia hasn’t controlled as expected on current treatments.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Hear when a new Chronic Phase Ph+ Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.